Journal
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
Volume 5, Issue 3, Pages -Publisher
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a018432
Keywords
-
Categories
Funding
- National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI-067665, AI-105684, AI063537, AI094745, AI-033774, AI-052733, AI-033142]
- National Heart, Lung, and Blood Institute (NHLBI) [HL-059842]
- Center for AIDS Research (CFAR) at the Albert Einstein College of Medicine [AI-51519]
- Aeras TB vaccine foundation
- Food and Drug Administration (FDA) [1U18 FD004012/01]
- Bill & Melinda Gates Grand Challenge award
- TB Vaccine Accelerator Program award
- FOOD AND DRUG ADMINISTRATION [U18FD004012] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059842] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI051519, K23AI067665, R01AI033774, R01AI033142, R37AI033142, R01AI052733, R21AI105684, R01AI094745, P01AI063537] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Accumulating evidence has documented a role for B cells and antibodies (Abs) in the immunity against Mycobacterium tuberculosis (Mtb). Passive transfer studies with monoclonal antibodies (mAbs) against mycobacterial antigens have shown protection against the tubercle bacillus. B cells and Abs are believed to contribute to an enhanced immune response against Mtb by modulating various immunological components in the infected host including the T-cell compartment. Nevertheless, the extent and contribution of B cells and Abs to protection against Mtb remains uncertain. In this article we summarize the most relevant findings supporting the role of B cells and Abs in the defense against Mtb and discuss the potential mechanisms of protection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
